{"id":87538,"date":"2026-05-14T19:12:12","date_gmt":"2026-05-14T13:42:12","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=87538"},"modified":"2026-05-14T19:12:15","modified_gmt":"2026-05-14T13:42:15","slug":"gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57\/","title":{"rendered":"GlaxoSmithKline Pharmaceuticals India Q4 FY26 Results: PAT Rs 277.86 Crore Up 5.7 Percent Dividend Rs 57 Per Share Record Date May 29"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><strong><a href=\"https:\/\/univest.in\/user\/stocks\/glaxo\/glaxosmithkline-pharmaceuticals-ltd-share-price-today\">GlaxoSmithKline<\/a> Q4 FY26<\/strong> results, announced on May 13, 2026, showed consolidated PAT of Rs 277.86 crore, up 5.7% YoY from Rs 262.87 crore in Q4 FY25. The <strong>GlaxoSmithKline Q4 FY26<\/strong> board also recommended a final dividend of Rs 57 per equity share for FY26, with record date May 29, 2026 and payment expected on or after July 1, 2026. Investors tracking <strong>GlaxoSmithKline Q4 FY26<\/strong> results will find complete analysis and FY27 outlook below.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2013 Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57\/#GlaxoSmithKline_Q4_FY26_Key_Financial_Highlights\" title=\"GlaxoSmithKline Q4 FY26 Key Financial Highlights\">GlaxoSmithKline Q4 FY26 Key Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57\/#GlaxoSmithKline_Q4_FY26_Performance_Analysis\" title=\"GlaxoSmithKline Q4 FY26 Performance Analysis\">GlaxoSmithKline Q4 FY26 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57\/#GlaxoSmithKline_FY27_Outlook\" title=\"GlaxoSmithKline FY27 Outlook\">GlaxoSmithKline FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57\/#Frequently_Asked_Questions_on_GlaxoSmithKline_Q4_FY26\" title=\"Frequently Asked Questions on GlaxoSmithKline Q4 FY26\">Frequently Asked Questions on GlaxoSmithKline Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57\/#What_is_GlaxoSmithKline_Q4_FY26_PAT\" title=\"What is GlaxoSmithKline Q4 FY26 PAT?\">What is GlaxoSmithKline Q4 FY26 PAT?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57\/#What_is_GlaxoSmithKline_Q4_FY26_dividend\" title=\"What is GlaxoSmithKline Q4 FY26 dividend?\">What is GlaxoSmithKline Q4 FY26 dividend?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/gsk-india-q4-fy26-results-pat-rs-277-86-crore-up-5-7-percent-dividend-rs-57\/#When_was_GlaxoSmithKline_Q4_FY26_announced\" title=\"When was GlaxoSmithKline Q4 FY26 announced?\">When was GlaxoSmithKline Q4 FY26 announced?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"GlaxoSmithKline_Q4_FY26_Key_Financial_Highlights\"><\/span><strong>GlaxoSmithKline Q4 FY26 Key Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th><strong>Metric<\/strong><\/th>\n<th><strong>Q4 FY26<\/strong><\/th>\n<th><strong>Q4 FY25 \/ YoY Change<\/strong><\/th>\n<\/tr>\n<tr>\n<td><strong>Consolidated PAT<\/strong><\/td>\n<td>Rs 277.86 crore<\/td>\n<td>Rs 262.87 crore (Q4 FY25) | +5.7% YoY<\/td>\n<\/tr>\n<tr>\n<td><strong>FY26 Final Dividend<\/strong><\/td>\n<td>Rs 57 per equity share<\/td>\n<td>Record date May 29, 2026 | Payment July 1, 2026+<\/td>\n<\/tr>\n<tr>\n<td><strong>NSE Ticker<\/strong><\/td>\n<td>GLAXO<\/td>\n<td>Sector: Pharmaceuticals | UK GSK Group<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"GlaxoSmithKline_Q4_FY26_Performance_Analysis\"><\/span><strong>GlaxoSmithKline Q4 FY26 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>GlaxoSmithKline Q4 FY26<\/strong> consolidated PAT growth of 5.7% YoY to Rs 277.86 crore reflects stable demand for prescription pharma products in India. <strong>GlaxoSmithKline Q4 FY26<\/strong> performance was driven by its core vaccine and pharmaceutical franchise, including Augmentin, Calpol, and Sensodyne brands. The company is a subsidiary of the UK-listed GSK plc.<\/p>\n<p>The <strong>GlaxoSmithKline Q4 FY26<\/strong> dividend of Rs 57 per equity share (face value Rs 10) represents a dividend yield of approximately 2.4% at prevailing prices. The <strong>GlaxoSmithKline Q4 FY26<\/strong> result was announced at the company&#8217;s 101st AGM preparation stage. Investors in <strong>GlaxoSmithKline Q4 FY26<\/strong> should note the board&#8217;s consistent dividend policy as a marker of operational confidence.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"GlaxoSmithKline_FY27_Outlook\"><\/span><strong>GlaxoSmithKline FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Post <strong>GlaxoSmithKline Q4 FY26<\/strong>, management focus will be on growing the prescription pharma, vaccines, and consumer healthcare portfolio in India. India&#8217;s pharmaceutical sector continues to grow at 9-11% per annum, providing structural support. Track <strong>GlaxoSmithKline Q4 FY26<\/strong> analyst views on the Univest Screener.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track live price and Q4 FY26 earnings updates.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_GlaxoSmithKline_Q4_FY26\"><\/span><strong>Frequently Asked Questions on GlaxoSmithKline Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_GlaxoSmithKline_Q4_FY26_PAT\"><\/span><strong>What is GlaxoSmithKline Q4 FY26 PAT?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>GlaxoSmithKline Q4 FY26<\/strong> consolidated PAT was Rs 277.86 crore, up 5.7% YoY from Rs 262.87 crore in Q4 FY25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_GlaxoSmithKline_Q4_FY26_dividend\"><\/span><strong>What is GlaxoSmithKline Q4 FY26 dividend?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The <strong>GlaxoSmithKline Q4 FY26<\/strong> board recommended a final dividend of Rs 57 per equity share for FY26. Record date is May 29, 2026 and payment is due on or after July 1, 2026 post AGM approval.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_was_GlaxoSmithKline_Q4_FY26_announced\"><\/span><strong>When was GlaxoSmithKline Q4 FY26 announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>GlaxoSmithKline Q4 FY26<\/strong> results were announced on May 13, 2026, through the company&#8217;s board meeting and exchange filings with BSE and NSE.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline Pharmaceuticals India Q4 FY26 results: PAT Rs 277.86 crore, up 5.7% YoY from Rs 262.87 crore. Final dividend Rs 57\/share, record date May 29, 2026. Full analysis.<\/p>\n","protected":false},"author":26,"featured_media":87831,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-87538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778766166:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["64"],"rank_math_focus_keyword":["GlaxoSmithKline Q4"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["GlaxoSmithKline Q4 FY26: PAT Rs 277.86 Cr Up 5.7% Dividend Rs 57 Per Share"],"rank_math_description":["GlaxoSmithKline Q4 FY26 results: PAT Rs 277.86 crore (+5.7% YoY). Dividend Rs 57\/share, record date May 29, 2026. GSK India pharmaceuticals Q4 FY26 full analysis."],"_thumbnail_id":["87831"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11507"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/14191149\/GlaxoSmithKline-Pharmaceuticals-India-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=87538"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87538\/revisions"}],"predecessor-version":[{"id":87832,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87538\/revisions\/87832"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/87831"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=87538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=87538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=87538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}